Alaya.bio
is developing a targeting polymeric nanoparticle
Alaya.bio
Our nanoparticle enhances the transduction efficiency of quiescent cells like T-cells, NK-cells while preserving their naive and memory phenotypes.
Alaya.bio
Our nanoparticle can be used either ex vivo or in vivo
Q&A

Questions asked by Alaya.bio
Answers provided by ChatGPT

Tell me about the future of immunotherapies and in particular of CAR-T therapies

Read answer
Question
#
1

Why are CAR-T therapies so expensive?

Read answer
Question
#
2

What are you referring to when mentioning the ongoing efforts to reduce the cost of CAR-T therapies?

Read answer
Question
#
3

Have you heard about rapid manufacturing process to produce faster and cheaper CAR-T therapies?

Read answer
Question
#
4

What about allogeneic strategies? Are allogeneic CAR-T therapies as effective as autologous CAR-T therapies?

Read answer
Question
#
5

What about in vivo CAR-T therapies (also called in situ CAR-T therapies)?

Read answer
Question
#
6

What are the results to date of CAR-T therapies against solid tumors?

Read answer
Question
#
7

Who are the key players (either biotech or pharma companies) developing CAR-T therapies?

Read answer
Question
#
8

What about new comers developing in situ strategies like Umoja, Interius, Sana, Tidal ?

Read answer
Question
#
9

Alaya.bio is a preclinical-stage biotech developing novel CAR-T therapies. The company has been co-founded by Dr. Cécile BAUCHE and Renaud VAILLANT.

Read answer
Question
#
10

Is it interesting to work for in vivo CAR-T companies like Alaya.bio?

Read answer
Question
#
11

Cécile BAUCHE and
Renaud VAILLANT
have formed a complementary and
experienced duo for the last 15 years.

Cécile
bauche
-CSO

Biotech leader with 20+ years' expertise in gene delivery technologies. Turning groundbreaking innovation into gene therapy products from lab to clinic.

View profile on linkedin
Renaud
Vaillant
-CEO

Accomplished biotech executive, passionate about innovation, disruptive technologies and patient outcomes. Guiding therapeutic products from inception to proof-of-concept and clinical trials.

View profile on linkedin
France Office
and Lab spaces

1 mail du Professeur
Georges Mathé

94800 Villejuif
FRANCE
US
Office

139
Main Street
Cambridge

MA 02142
USA

NEWS

#02 Alaya.bio announces significant collaboration
with leading global cancer center to advance
‍in situ CAR-T Therapy

Download our press release

#01 Alaya.bio acquires key assets from Ixaka France, accelerating the progress of its novel in vivo CAR immunotherapy platform

Download our press release